PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

Impact · against what's priced in

The article provides no new catalysts for PGEN, as the commercial success of Papzimeos and European expansion are already reflected in the 50% share price rally. However, the upcoming Oct. 30 FDA decision for Inovio's INO-3107 represents a material risk to PGEN's current monopoly.

PGEN+0.00: No priced-in read yet

PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

What matters in this story

FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting

PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

What matters in this story

FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting

How each ticker is affected

Connected tickers

Track these names every morning.

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives

Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

What matters in this story

Next reads from the same story arc

FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting

PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

What matters in this story

Next reads from the same story arc

FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting

How each ticker is affected

Connected tickers

Track these names every morning.

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives

Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology